Carboplatin: current status and future prospects

Cancer Treatment Reviews

Volumn 15, Issue SUPPL. B, 1988, Pages 17-32

  Canetta, R ^a   Bragman, K ^b   Smaldone, L ^a   Rozencweig, M ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b Bristol Myers Company ^*  (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; ETOPOSIDE; METHOTREXATE;

CLINICAL TRIAL; HEAD AND NECK CANCER; HUMAN; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; OVARY CANCER; REVIEW; UROGENITAL TRACT CANCER;

ANTINEOPLASTIC AGENTS; CARBOPLATIN; CARCINOMA, SMALL CELL; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIALS; DRUG EVALUATION; FEMALE; HEAD AND NECK NEOPLASMS; HUMAN; LUNG NEOPLASMS; MALE; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; UROGENITAL NEOPLASMS;

EID: 0023764208     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/0305-7372(88)90031-X     Document Type: Article

References (112)

1. A comparison of the toxicity and efficacy of cisplatin and carboplatin in advanced ovarian cancer
2. Platinum analogs in recurrent and advanced head and neck cancer: a Southwest Oncology Group and Wayne State University study
3. Phase I trial of carboplatin-cyclophosphamide and iproplatin-cyclophosphamide in advanced ovarian cancer: a Southwest Oncology Group study
4. Carboplatin and recurrent childhood brain tumors
5. Comparative toxicity of cisplatin, carboplatin and iproplatin in combination with cyclophosphamide in patients with advanced epithelial ovarian cancer
6. A phase II study of carboplatin in advanced squamous cell carcinoma of the cervix (A Gynecologic Oncology Group Study)
7. Animal screening of new platinum derivatives
8. Phase I study of carboplatin (CBDCA) in children with cancer
9. A phase II study of carboplatin in advanced or metastatic stomach cancer
10. Carboplatin and VP-16-213 in previously untreated patients with small cell lung cancer
11. Phase II-III trial of mitomycin-vinblastine-cisplatin (MVP); vinblastine-cisplatin (VP); MVP alternating with cyclophosphamide-adriamycin methotrexate-procarbazine (MVP/CAMP); CBDCA followed by MVP; and CHIP followed by MVP in patients with metastatic non-small cell lung cancer (NSCLG): An ECOG study
12. Phase II trial of carboplatin in advanced breast carcinoma: Cancer and Leukemia Group B study
13. A pilot study of carboplatin plus cyclophosphamide and doxorubicin in advanced ovarian carcinoma
14. JM8 development and clinical projects
15. Paraplatin phase II studies in head and neck cancer
16. Carboplatin: the clinical spectrum to date
17. Phase II studies of a novel antiforate CB3717, and the platinum analogues JM8 and JM9, in mesothelioma of pleura and peritoneum
18. Phase I-II study of intraperitoneal CBDCA in patients with advanced ovarian cancer
19. Carboplatin as salvage in ovarian cancer: Unpredictable myelotoxicity
20. Low toxicity and significant tumor responses in phase II trials of carboplatin in head and neck, non-small cell lung, urothelial, and ovarian cancers
21. Antitumor activity of 24-hour CBDCA infusions in metastatic transitional cell carcinoma
22. Limited activity of carboplatin in malignant lymphoma
23. Carboplatin, an active drug in advanced head and neck cancer
24. Randomized trial of neoadjuvant cisplatin and fluorouracil versus carboplatin and fluorouracil in patients with advanced head and neck cancer
25. Pilot study of cyclophosphamide plus carboplatin in advanced ovarian carcinoma
26. Pilot study with carboplatin/etoposide as first line chemotherapy in advanced ovarian carcinoma (stage III, IV)
27. Carboplatin (NSC 241240): An active platinum analog for the treatment of squamous cell carcinoma of the head and neck
28. Phase I/II trial with simultaneous weekly carboplatin (CBDCA) and conventional radiotherapy (RT) for patients with unresectable head and neck cancer
29. Phase II study of carboplatin in patients with ovarian carcinoma: A National Cancer Institute of Canada Clinical Trials Group study
30. Pharmacokinetics of carboplatin: IV vs. IP administration
31. Phase I pediatric trial of cisdiammine-1, 1-cyclobutane dicarboxylate platinum II (NSC 241240, CBDCA)
32. Phase II study ofJM8, a new platinum analog, in advanced ovarian carcinoma
33. Phase II trial of carboplatin in advanced malignant melanoma
34. Second line chemotherapy with carboplatin or cisplatin in advanced ovarian cancer: Evaluation of cross resistance
35. A Phase I-II Trial of Carboplatin and 5-fluorouracil combination chemotherapy in advanced carcinoma of the head and neck
36. Results of NCI-sponsored phase I trials with carboplatin
37. Randomized phase II trial of carboplatin vs. iproplatin in solid tumors
38. Phase II study of carboplatin in recurrent or advanced endometrial cancer
39. A phase II trial of carboplatin in advanced or metastatic transitional carcinoma of the bladder
40. Cisplatin or carboplatin in combination chemotherapy for advanced ovarian cancer
41. Carboplatin and 120 hours 5-fluorouracil in patients with colorectal cancer
42. A phase I high dose escalation study of carboplatin
43. Pilot study with carboplatin/vincristine/etoposide as first line therapy in extensive small cell lung cancer
44. Alternating scheme of chemotherapy with carboplatin, VP-16, Ifosfamide, doxorubicin and vincristine plus radiotherapy in the treatment of small cell lung cancer. Preliminary results
45. A pilot study of paraplatin and chlorambucil in advanced epithelial ovarian cancer
46. What dose of carboplatin can be combined with etoposide and bleomycin in patients with testicular cancer?
47. Single-agent carboplatin: Effective non-toxic treatment for advanced seminoma
48. Phase II study of carboplatin for head and neck cancer
49. Phase II study of carboplatin in previously untreated patients with metastatic small cell lung carcinoma
50. A phase I study of a carboplatin plus etoposide chemotherapy in patients with advanced thoracic cancer
51. Phase II study of carboplatin in advanced upper gastrointestinal tract malignancy
52. Toxicity of carboplatin (CBDCA) in combination with methotrexate (MTX) in patients with metastatic squamous cell carcinoma of the head and neck (SCCHN)
53. Phase I study of carboplatin: A Cooperative Group Study in Japan
54. Phase II trial of carboplatin in ovarian cancer
55. Clinical study of intraperitoncal carboplatin in ovarian cancer therapy
56. Iproplatin or carboplatin in extensive non-small cell lung cancer
57. Phase I trial of carboplatin in relapsed/refractory adult leukemia
58. Carboplatin, ifosfamide, etoposide with mid-course vincristine and thoracic radiotherapy for limited stage small cell lung cancer
59. Randomized study of CHIP versus CBDCA in recurrent and metastatic cervix cancer
60. Phase II evaluation of carboplatin (CBDCA) in advanced endometrial cancer: A collaborative trial of the North Central Cancer Treatment Group and Mayo Clinic
61. The clinical pharmacology of intraperitoneal carboplatin: a phase I/II study of the Northern California Oncology Group
62. Head and neck cancer: Neoadjuvant chemotherapy with ftorafur and carboplatin
63. A phase II trial of carboplatin (CBDCA, NSC 241240) in advanced ovarian cancer patients
64. Phase II trial of carboplatin (JM8) in the treatment of patients with mesothelioma (M)
65. Phase I and II of carboplatin
66. Phase II trial of carboplatin in advanced bladder cancer
67. A phase II study of carboplatin in metastatic transitional cell carcinoma of the bladder
68. Carboplatin/cyclophosphamide as combination-chemotherapy in advanced ovarian cancer
69. A phase I trial of infusion carboplatin in relapsed acute leukemia
70. Phase II trial of carboplatin in patients with advanced germ cell tumors refractory to cisplatin
71. Treatment of poor risk non-seminomatous germ cell tumor (NSGCT) patients (pts) with carboplatin (CBDCA) plus Etoposide (E) plus Bleomycin (B)
72. Phase II study of carboplatin
73. Carboplatin: Activity in patients with head and neck, renal cell and ovarian carcinomas
74. Carboplatin (CBDCA) and continuous infusion 5-fluorouracil (5FU) in advanced head and neck cancer
75. Phase II trial ofcarboplatin in non-small cell lung cancer
76. High-dose carboplatin in refractory ovarian cancer patients
77. First line carboplatin 24 hours infusion of patients with disseminated oat cell carcinoma of the lung
78. CBDCA: A phase II evaluation in advanced colorectal carcinoma
79. Cis-diammine-1, 1-cyclobutane dicarboxylate platinum II (carboplatin) in the treatment of testicular germ-cell tumours: A preliminary report
80. Carboplatin for advanced colorectal carcinoma: A phase II study
81. A phase II trial of carboplatin in advanced ovarian cancer
82. Phase I trial of diethyldithiocarbamate as a chemoprotector of cisplatin toxicity
83. A phase II study of carboplatin in locally advanced and metastatic transitional cell carcinoma of the urinary tract
84. Carboplatin plus adriamycin plus cytoxan for epithelial ovarian cancer: A study of feasibility
85. Carboplatin: The clinical evaluation strategy
86. Phase II trial with carboplatin/5FU in previously untreated patients with advanced squamous cell carcinoma of the head and neck
87. European studies with cisplatin and cisplatin analogs in advanced ovarian cancer
88. High dose continuous infusion carboplatin: A phase I study
89. Carboplatin (paraplatin: JM8) and etoposide (VP-16) as first-line combination therapy for small cell lung cancer
90. Carboplatin (Cp), VP-16 (V) and ifosfamide (I) intensive chemotherapy (CT) for small cell lung carcinoma (SCLC)
91. Treatment of small cell carcinoma of the lung with paraplatin (carboplatin): Single-agent, combination, and high-dose therapy
92. Carboplatin in small cell lung cancer: Conventional and high dose studies
93. Carboplatin: A very active new cisplatin analog in the treatment of small cell lung cancer
94. Carboplatin: A new platinum analog in the treatment of epidermoid carcinoma of the esophagus
95. The efficacy and toxicity of carboplatin in previously treated patients with advanced ovarian cancer
96. The UCL-clinical oncology group experience with paraplatin
97. Carboplatin and cyclophosphamide combination chemotherapy in advanced ovarian cancer
98. Intraperitoncal carboplatin for refractory ovarian cancer: A phase I study
99. High dose carboplatin in refractory ovarian cancer: A phase II trial assessing the protective role against myclosuppression by diethyldithiocarbomate (DDTC)
100. Carboplatin and cyclophosphamide in relapsing ovarian cancer patients
101. A pilot study of CHAC-1
102. Carboplatin replacing cisplatin in combination chemotherapy for ovarian cancer
103. Standard combination chemotherapy versus two carboplatin containing regimens in SCLC
104. Phase I study with carboplatin-5FU to patients with advanced head and neck carcinomas
105. Carboplatin in advanced, refractory germ cell neoplasms: A phase II Eastern Cooperative Oncology Group Study
106. Platinum analogue combination chemotherapy: Cisplatin and carboplatin
107. Dose finding studies with carboplatin, ifosfamide, etoposide and mesna in patients with advanced non-small cell lung cancer
108. Randomized phase II trial of iproplatin and carboplatin in advanced breast cancer
109. Treatment of recurrent glioma with carboplatin
110. Paraplatin (carboplatin) in ovarian cancer
111. Phase II randomized trial cisplatin versus JM8 (carboplatin) in 112 ovarian cancer patients, stages III and IV
112. Phase II study of cis-diammine-1, 1, cyclobutane dicarboxylate platinum II (CBDCA, NSC 241240) in non-small cell and small cell lung cancer